Simponi 50 mg solution for injection, pre filled pen

  • Name:

    Simponi 50 mg solution for injection, pre filled pen

  • Company:
    info
  • Active Ingredients:

    Golimumab

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 17/06/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 13/6/2019

Click on this link to Download PDF directly

MSD Ireland (Human Health) Limited

MSD Ireland (Human Health) Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Adempas Film Coated Tablets Active Ingredients Riociguat
Medicine Name Arcoxia 30 60 90 120 film-coated tablets Active Ingredients Etoricoxib
Medicine Name Atozet 10mg/10mg, 10mg/20mg, 10mg/40mg and 10mg/80mg film-coated tablets Active Ingredients Atorvastatin calcium trihydrate, ezetimibe
Medicine Name Bridion Active Ingredients Sugammadex sodium
Medicine Name Cancidas 50mg Powder for concentrate for solution for infusion Active Ingredients caspofungin acetate
Medicine Name Cancidas 70mg Powder for concentrate for solution for infusion Active Ingredients caspofungin acetate
Medicine Name Cerazette 75 microgram film-coated tablet Active Ingredients Desogestrel
Medicine Name Cozaar 12.5mg, 50mg & 100mg Film-coated Tablets Active Ingredients Losartan potassium
Medicine Name Cozaar 2.5mg/ml Powder and Solvent for Oral Suspension Active Ingredients Losartan potassium
Medicine Name Cozaar COMP 50 mg/12.5 mg, 100 mg/12.5 mg, 100 mg/25 mg film-coated tablets Active Ingredients Hydrochlorothiazide, Losartan potassium
Medicine Name Cubicin 350mg Powder for Solution for injection or infusion Active Ingredients Daptomycin
Medicine Name Cubicin 500mg powder for solution for injection or infusion Active Ingredients Daptomycin
Medicine Name Delstrigo 100 mg/300 mg/245 mg film-coated tablets Active Ingredients Lamivudine, Tenofovir disoproxil fumarate, Doravirine
Medicine Name Diprosalic Scalp Application Active Ingredients Betamethasone dipropionate, Salicylic Acid
Medicine Name Elocon Cream Active Ingredients Mometasone Furoate
Medicine Name Elocon Ointment Active Ingredients Mometasone Furoate
Medicine Name Elocon Scalp Lotion Active Ingredients Mometasone Furoate
Medicine Name EMEND 125 mg hard capsules Active Ingredients Aprepitant
Medicine Name EMEND 80 mg hard capsules Active Ingredients Aprepitant
Medicine Name EMEND 80mg, 125mg hard Capsules Active Ingredients Aprepitant
Medicine Name Esmeron Active Ingredients Rocuronium Bromide
Medicine Name EZETROL 10 mg Tablets Active Ingredients ezetimibe
Medicine Name FOSAMAX Once Weekly 70 mg Tablets Active Ingredients Alendronate Sodium Trihydrate
Medicine Name FOSAVANCE Active Ingredients Alendronate Sodium Trihydrate, Colecalciferol (Vitamin D3)
Medicine Name GARDASIL Active Ingredients human papillomavirus vaccine
1 - 0 of 84 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 17 June 2019 PIL

Reasons for updating

  • Change to section 5 - how to store or dispose
  • Change to section 6 - date of revision

Updated on 13 June 2019 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SPC change details: shelf life extension and introduction of room temperature storage option

 

Updated on 8 April 2019 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 8 April 2019 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 4.8 – addition of “Lichenoid reactions” to Rare side effects under “Skin and subcutaneous tissue disorders”

 

Updated on 12 March 2019 PIL

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - use in children and adolescents
  • Change to section 2 - driving and using machines
  • Change to section 2 - excipient warnings
  • Change to section 3 - use in children/adolescents
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - what the product contains
  • Change to section 6 - date of revision

Updated on 12 March 2019 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Broadening of the pJIA indication in the EU; added information on “Traceability” and “Excipients”; changed reference “Simponi” to “golimumab”; change to excipients naming convention; adverse drug reaction changed to adverse reaction

 

Updated on 31 October 2018 PIL

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 6 - date of revision

Updated on 31 October 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 4.2  & 4.4 – update the name of the Patient Reminder Card, previously called Patient Alert Card

 

Updated on 20 July 2018 PIL

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 6 - date of revision

Updated on 20 July 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

update the information on maintenance regimen for patients with ulcerative colitis weighing <80 kg based on analyses of PK, efficacy and safety from the pivotal C0524T18 study
 

Updated on 3 May 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 1 May 2018 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 4.4 – update of section “Haematologic reactions”; Section 4.8 – update of side effects on section “Blood and lymphatic system disorders

Updated on 26 April 2018 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 22 February 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 22 February 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SPC change details:  Change to section 4.4 – under subheading ‘Skin cancers’ - Merkel cell carcinoma has been added to the warning  about Melanoma (the same warning applies to both now),  Section 4.8 – Undesirable effects – Merkel cell cancer occurrence frequency has been changed from ‘not known’ to ‘rare’ and Change to Section 10 - Date of revision of the text has been updated

Updated on 21 February 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 21 February 2017 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 22 December 2016 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Shelf-life changed from 18 months to 22 months

Updated on 24 November 2016 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SPC change details:   Sections 4.8 and section 5.1 have been updated with the results from the extension study in UC and nr Axial SpA.  PLEASE NOTE: The SPC for 50mg pre-filled pen and for 50mg pre-filled syringe have been joined with this variation update. Therefore, the number of sections now reflect the information for both 50mg presentations(pen and syringe). However, there are no changes to the text itself in any of the sections which are joint (sections 1, 2, 3, 4.4, 6.4, 6.5, 6.6 and 8).

Updated on 19 July 2016 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

A new indication - treatment of polyarticular juvenile idiopathic arthritis (pJIA) has been added. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 10 of the SPC have been updated.

Updated on 15 July 2016 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use
  • Change to date of revision
  • Change to dosage and administration

Updated on 12 January 2016 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Sections that have changed:  Change to Section 4.4 - Special warnings and precautions for use, Change to Section 4.8 - Undesirable and Change to Section 10 - Date of revision of the text

SPC change details:   The SPC has been revised to:  a) Clarify that infections may present as disseminated rather than localized disease;  b)  Emphasize the risks of invasive fungal infections;  c) Clarify that leukemia has been observed in clinical trials in addition to the post-marketing setting;  d) Clarify that cases of congestive heart failure (CHF) with fatal outcomes have been observed.

Updated on 11 January 2016 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 7 August 2015 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company


SPC change details:    A new indication treatment of Non radiographic Axial SpondyloArthritis has been added recently. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SPC have been updated. The SPC that reflects these changes has been uploaded to medicines.ie on 13/07/2015. However, the correction has to be made to “Reporting of suspected adverse reactions” paragraph in section 4.8, so the SPC version uploaded in August captures this correction (there are no other changes to any other section).
Sections that have changed:  Change to Section 4.8 - Undesirable effects - how to report a side effect

 

Updated on 13 July 2015 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to date of revision

Updated on 10 July 2015 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Sections that have changed:     Change to Section 4.1 - Therapeutic indications, Change to Section 4.2 - Posology and method of administration, Change to Section 4.4 - Special warnings and precautions for use, Change to Section 4.8 - Undesirable effects, Change to Section 5.1 - Pharmacodynamic properties, Change to Section 5.2 - Pharmacokinetic properties, Change to Section 10 - Date of revision of the text

Updated on 2 June 2015 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text
  • Change to separate SPCs covering individual presentations

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Sections that have changed:  change to Section 6.3 - Shelf life, Change to Section 10 - Date of revision of the text, Change to separate SPCs covering individual presentations

 

SPC change details:   Shelf-life changed from 1 year to 18 months and text revision date from January 2015 to May 2015

Updated on 23 January 2015 SmPC

Reasons for updating

  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company


Sections 9 & 10 
 Reasons for submission: Approval of PSUV/058 IFU-Indicator

Updated on 22 January 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to dosage and administration

Updated on 6 November 2014 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to Section 4.8 - Undesirable effects, Change to Section 5.1 - Pharmacodynamic properties

Approval of Type II variation to register bullous skin reactions as an uncommon adverse reaction 


Updated on 5 November 2014 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 7 August 2014 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Further updates to section 4.8 of SmPCs for Simponi following approval of Type II Variation - Addition of data on the long-term extension of the subcutaneous Phase 3 RA (C0524T05, C0524T06, and C0524T11), PsA (C0524T08), and AS (C0524T09) clinical studies & the provision of the final (268-week) CSRs for these 5 clinical studies to fulfill a follow-up measure and to update the SmPC regarding the frequency of certain adverse effects.

Updated on 5 August 2014 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Addition of data on the long-term extension of the subcutaneous Phase 3 RA (C0524T05, C0524T06, and C0524T11), PsA (C0524T08), and AS (C0524T09) clinical studies & the provision of the final (268-week) CSRs for these 5 clinical studies to fulfill a follow-up measure and to update the SmPC regarding the frequency of certain adverse effects

Updated on 8 July 2014 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The changes made to the SmPC are as follows:

 

Section 4.2 Posology and method of administration

‘for all of the above indications’ now precedes the 2 paragraphs on clinical response under RA, PsA and AS.

 

Section 4.8 Undesirable effects

‘within each frequency grouping, adverse reactions are presented in order of decreasing seriousness’ has been added before the table of ADRs.

 
Amendment of the AE reporting details to HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971, Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie

 

 

Section 5.1 Pharmacodynamic properties

‘HAQ’ has been replaced with ‘HAQ DI’

 

Section 6.5 Nature and content of container

1.0ml has been deleted from the description of type I glass: (1.0ml Type I glass)

 

Other changes have been applied throughout:

·        ‘ml’ now reads ‘mL

·        ‘medications’ have been replaced with ‘medicines

·        ‘Older people’ has been replace with ‘Elderly’

Updated on 7 July 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to instructions about missed dose
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 19 March 2014 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision

Updated on 24 October 2013 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to further information section
  • Change to date of revision
  • Change to dosage and administration

Updated on 24 October 2013 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Wording added in section 4.1 Therapeutic Indication:

Patients with bodyweight greater than 100 kg

In patients with RA, PsA or AS with a body weight of weighing more than 100 kg who do not achieve an adequate clinical response after 3 or 4 doses…………

 

 

Ulcerative colitis (UC)

Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6‑mercaptopurine (6‑MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

 

Wording added in section 4.2 Posology and method of administration:

 

Ulcerative colitis

Patients with body weight less than 80 kg

Simponi given as an initial dose of 200 mg, followed by 100 mg at week 2, then 50 mg every 4 weeks, thereafter (see section 5.1).

 

Patients with body weight greater than or equal to 80 kg

Simponi given as an initial dose of 200 mg, followed by 100 mg at week 2, then 100 mg every 4 weeks, thereafter (see section 5.1).

 

During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice guidelines.

 

Available data suggest that clinical response is usually achieved within 12‑14 weeks of treatment (after 4 doses). Continued therapy should be reconsidered in patients who show no evidence of therapeutic benefit within this time period.

 

Method of administration paragraph includes the sentence: If multiple injections are required, the injections should be administered at different sites on the body.

 

Wording added in section 4.4 Special warnings and precautions for use:

 

Lymphoma and leukaemia

………..

Rare post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with other TNF-blocking agents (see section 4.8). This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. The majority of cases have occurred in adolescent and young adult males with nearly all on concomitant treatment with azathioprine (AZA) or 6‑mercaptopurine (6–MP) for inflammatory bowel disease. The potential risk with the combination of AZA or 6‑MP and Simponi should be carefully considered. A risk for the development for hepatosplenic T‑cell lymphoma in patients treated with TNF-blockers cannot be excluded.

 

Malignancies other than lymphoma

In the controlled portions of the Simponi Phase IIb and Phase III clinical trials in RA, PsA, AS, and UC,

 

Colon dysplasia/carcinoma

It is not known if golimumab treatment influences the risk for developing dysplasia or colon cancer. All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before therapy and throughout their disease course. This evaluation should include colonoscopy and biopsies per local recommendations. In patients with newly diagnosed dysplasia treated with Simponi, the risks and benefits to the individual patient must be carefully reviewed and consideration should be given to whether therapy should be continued.

 

Potential for Medication errors

Simponi is registered in 50 mg and 100 mg strengths for subcutaneous administration. It is important that the right strength is used to administer the correct dose as indicated in the posology (see section 4.2). Care should be taken to provide the right strength to ensure that patients are not underdosed or overdosed.

 

Wording added in section 4.8 Undesirable effects:

 

There have been many changes in the frequencies of ADRs:

Reduction in frequency

Increase in frequency

Common to uncommon

Depression, insomnia, constipation, alopecia, dermatitis, chest discomfort

Rare to uncommon

Pancytopenia, renal disorders

Common to rare

Impaired healing

 

Uncommon to rare

Tuberculosis, pyelonephritis, infective bursitis

 

Added:

‘Not known’ frequency – hepatosplenic T-cell lymphoma

 

Within the description of adverse drug reactions the UC trial data has been added making extensive changes to the number of golimumab treated patients, the number of control patients, the incidence per 100 subject years. Additional information has been added to the following ADRs:

Infections

In the controlled period of UC trials of golimumab induction, serious infections were observed in 0.8% of golimumab-treated patients compared with 1.5% of control-treated patients.

Malignancies

Malignancies other than lymphoma

Through approximately 2 years of follow-up, the incidence of non-lymphoma malignancies (excluding non-melanoma skin cancer) was similar to the general population.

Liver enzyme elevations

In the controlled period of the UC pivotal trials of golimumab induction , mild ALT elevations (> 1 and < 3 x ULN) occurred in similar proportions of golimumab-treated and control patients (8.0% to 6.9%, respectively). In controlled and uncontrolled periods of the UC pivotal trials with a mean follow-up of 1 year, the incidence of mild ALT elevations was 17.4% in patients receiving golimumab during the maintenance portion of the UC study.

……..

In the controlled periods of the pivotal UC trials, of golimumab induction, ALT elevations ≥ 5 x ULN occurred in similar proportions of golimumab-treated patients compared to placebo-treated patients (0.3% to 1.0%, respectively). In the controlled and uncontrolled periods of the pivotal UC trials with a mean follow-up of 1 year, the incidence of ALT elevations ≥ 5 x ULN was 0.7% in patients receiving golimumab during the maintenance portion of the UC study.

 

Wording added in section 5.1 Pharmacodynamic properties:

Immunosuppressants’ has been added to the Pharmacotherapeutic group: Immunosuppressants, tumour necrosis factor alpha (TNF‑α) inhibitors, ATC code: L04AB06

 

Ulcerative colitis

The efficacy of Simponi was evaluated in two randomized, double-blind, placebo-controlled clinical studies in adult patients.

 

The induction study (PURSUIT-Induction) evaluated patients with moderately to severely active ulcerative colitis (Mayo score 6 to 12; Endoscopy subscore ≥ 2) who had an inadequate response to or failed to tolerate conventional therapies, or were corticosteroid dependent. In the dose confirming portion of the study, 761 patients were randomized to receive either 400 mg Simponi SC at Week 0 and 200 mg at Week 2, 200 mg Simponi SC at Week 0 and 100 mg at Week 2, or placebo SC at Weeks 0 and 2. Concomitant stable doses of oral aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted. The efficacy of Simponi through week 6 was assessed in this study.

 

The results of the maintenance study (PURSUIT-Maintenance) were based on evaluation of 456 patients who achieved clinical response from previous induction with Simponi. Patients were randomized to receive Simponi 50 mg, Simponi 100 mg or placebo administered subcutaneously every 4 weeks. Concomitant stable doses of oral aminosalicylates, and/or immunomodulatory agents were permitted. Corticosteroids were to be tapered at the start of the maintenance study. The efficacy of Simponi through week 54 was assessed in this study.

 

Table 6

Key efficacy outcomes from PURSUIT - Induction and PURSUIT - Maintenance

PURSUIT-Induction

 

 

Placebo

N = 251

Simponi

200/100 mg

N = 253

Percentage of patients

Patients in clinical response at week 6a

30%

51%**

Patients in clinical remission at week 6b

6%

18%**

Patients with mucosal healing at week 6c

29%

42%**

PURSUIT-Maintenance

 

 

Placebod

N = 154

Simponi

50 mg

N = 151

Simponi

100 mg

N = 151

Percentage of patients

Maintenance of response (Patients in clinical response through Week 54)e

31%

47%*

50%**

Sustained remission (Patients in clinical remission at both Week 30 and Week 54)f

16%

23%g

28%*

N = number of patients

**    p ≤ 0.001

*      p ≤ 0.01

a      defined as a decrease from baseline in the Mayo score by ≥ 30% and ≥ 3 points, accompanied by a decrease in the rectal bleeding subscore of ≥ 1 or a rectal bleeding subscore of 0 or 1.

b      Defined as a Mayo score ≤ 2 points, with no individual subscore > 1

c      Defined as 0 or 1 on the endoscopy subscore of the Mayo score.

d      Simponi induction only.

e      Patients were assessed for UC disease activity by partial Mayo score every 4 weeks (loss of response was confirmed by endoscopy). Therefore, a patient who maintained response was in a state of continuous clinical response at each evaluation through Week 54.

f       A patient had to be in remission at both weeks 30 and 54 (without demonstrating a loss of response at any time point through Week 54) to achieve durable remission.

g      In patients weighing less than 80 kg, a greater proportion of patients who received 50 mg maintenance therapy showed sustained clinical remission compared with those who received placebo .

 

More Simponi-treated patients demonstrated sustained mucosal healing (patients with mucosal healing at both Week 30 and Week 54) in the 50 mg group (42%, nominal p < 0.05) and 100 mg group (42%, p < 0.005) compared with patients in the placebo group (27%).

 

Among the 54% of patients (247/456) who were receiving concomitant corticosteroids at the start of PURSUIT-Maintenance, the proportion of patients who maintained clinical response through Week 54 and were not receiving concomitant corticosteroids at Week 54 was greater in the 50 mg group (38%, 30/78) and 100 mg group (30%, 25/82) compared with the placebo group (21%, 18/87). The proportion of patients who eliminated corticosteroids by Week 54 was greater in the 50 mg group (41%, 32/78) and 100 mg group (33%, 27/82) compared with the placebo group (22%, 19/87).

 

At Week 6, Simponi significantly improved quality of life as measured by change from baseline in a disease specific measure, IBDQ (inflammatory bowel disease questionnaire). Among patients who received Simponi maintenance treatment, the improvement in quality of life as measured by IBDQ was maintained through week 54.

 

Wording added in section 5.2 Pharmacokinetic properties:

Elimination

………..

Following induction doses of 200 mg and 100 mg golimumab at week 0 and 2, respectively, and maintenance doses of 50 mg or 100 mg golimumab subcutaneously every 4 weeks thereafter to patients with UC, serum golimumab concentrations reached steady state approximately 14 weeks after the start of therapy. Treatment with 50 mg or 100 mg golimumab subcutaneous every 4 weeks during maintenance resulted in a mean steady-state trough serum concentration of approximately 0.9 ± 0.5 mg/ml and 1.8 ± 1.1 mg/ml, respectively.

 

In UC patients treated with 50 mg or 100 mg golimumab subcutaneously every 4 weeks, concomitant use of immunomodulators did not have a substantial effect on steady-state trough levels of golimumab.

 

Linearity

………. Following a single SC dose in healthy subjects, approximately dose-proportional pharmacokinetics were also observed over a dose range of 50 mg to 400 mg.

 

Wording added in section 6.6 Special precautions for disposal and other handling:

Simponi should not be used if the solution is discoloured, cloudy or containing visible foreign particles. (this sentence has been deleted from section 6.5 and added to section 6.6)

Updated on 6 September 2013 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 6 September 2013 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company



Section 4.2 and 4.4

‘Elderly patients’ has been replaced with ‘older people’.

 

Section 4.8:

‘Interstitial lung disease’ has been moved from Rare in the tabulated list of ADRs to Uncommon within SOC, thoracic and mediastinal disorders.

 

In line with the updated QRD template and Appendix V the following text will be added for reporting of suspected adverse reactions:

Reporting Suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Pharmacovigilance Section, Irish Medicines Board, Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace IRL – Dublin 2

Tel: +353 1 6764971

Fax: +353 1 6762517

Website: www.imb.ie

e-mail: imbpharmacovigilance@imb.ie

 

Updated on 5 August 2013 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Wording added in section 4.4:


Vaccinations/therapeutic infectious agents

Patients treated with Simponi may receive concurrent vaccinations, except for live vaccines (see sections 4.5 and 4.6). In patients receiving anti-TNF therapy, No limited data are available on the response to vaccination with live vaccines, risk of infection or on the secondary transmission of infection by with the administration of live vaccines to patients receiving Simponi. Use of live vaccines could result in clinical infections, including disseminated infections.

 

Other uses of therapeutic infectious agents such as live attenuated bacteria (e.g., BCG bladder instillation for the treatment of cancer) could result in clinical infections, including disseminated infections. It is recommended that therapeutic infectious agents not be given concurrently with Simponi.

 

Wording added in section 4.5:

 

Live vaccines/therapeutic infectious agents

Live vaccines should not be given concurrently with Simponi (see sections 4.4 and 4.6).

Therapeutic infectious agents should not be given concurrently with Simponi (see section 4.4).

Updated on 2 August 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to date of revision

Updated on 24 June 2013 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 1 May 2013 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Addition of text on TB risks/prophylaxis in section 4.4 :

Cases of active tuberculosis have occurred in patients treated with Simponi during and after treatment for latent tuberculosis. Patients receiving Simponi should be monitored closely for signs and symptoms of active tuberculosis, including patients who tested negative for latent tuberculosis, patients who are on treatment for latent tuberculosis, or patients who were previously treated for tuberculosis infection.”

Updated on 30 April 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to further information section
  • Change to date of revision

Updated on 2 January 2013 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The changes made to the SmPC are as follows:

·       Warnings on concomitant use with other biologicals
Data based on a summary of published information from studies where anti-TNF treatment has been combined with another biological DMARD has resulted in updates to sections 4.4 and 4.5 of the SmPC in order to add a warning and updated information regarding concomitant use of golimumab/infliximab with other biological therapeutics.

 

·        MCC and melanoma safety warning
Following assessment melanoma is considered a drug class effect based on postmarketing data and the reporting rate associated with these data across TNF inhibitors, including infliximab and golimumab. The frequency category  is “rare” for of melanoma and "not known" for Merkel cell carcinoma, this has resulted in updates to sections 4.4 and 4.8 of the SmPC to add a warning and safety information regarding cases of melanoma and MCC. In addition, Section 4.4, subsection Malignancies, of the SmPC has been updated to advise that periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.

 

Updated on 20 December 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision

Updated on 26 September 2012 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The following changes to the SmPC were adopted:

  •  Addition of Rare side effect 'skin exfoliation' to section 4.8 Undesirable effects, under Skin and subcutaneous tissue disorders.

Updated on 26 September 2012 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 24 February 2012 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The changes to the product information (PI) include:

  • Inclusion of Nausea to section 4.8 of the SmPC and section 4 of the PIL.
  • Updates to the SmPC and PIL in line with QRD 8.0 for all other affected sections – PI Standard layout and terminology.

Updated on 23 February 2012 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 6 October 2011 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Correction to replace the reference to 'Pre-Filled Syringe' in sections 2 and 4.4.
Minor correction to section 4.5 to remove reference to 'section 4.6' in the Concurrent use with anakinra and abatacept paragraph.

Updated on 26 September 2011 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Following a comprehensive review of clinical trial safety information for Simponi (golimumab) through approximately 3 years (Week 160), it was determined that the Simponi Core Reference Label required updating to provide the most recent clinical data and reflect the evolving safety profile of this product.

Scope
Section 4.8 of the SmPC is updated to include new clinical trial safety information for infections, malignancies, neurological events and liver enzyme elevations.

Updated on 23 September 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to further information section
  • Change to date of revision

Updated on 20 June 2011 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Indication extension: PsA structural damage
Scope: Extension of the indication to include psoriatic arthritis (PsA) structural damage. Section 4.1 has been updated to add the reduction in the rate of progression of peripheral joint damage in (PsA).
Section 5.1 is updated regarding maintenance of the effects in signs and symptoms and physical function in PsA patients.
Background: wording has been added to the PsA indication to reflect data on structural joint damage measured by X-ray. Changes to section 5.1 are based on newly submitted X-ray data from the long-term extension of study C0524T08. This study was the basis for the initial approval of PsA.

Leukemia and sarcoidosis
Scope: Update of section 4.8 of the SmPC regarding the frequency of leukaemia and inclusion of sarcoidosis, the latter in response to a CHMP request.
Background: The changes are in line with earlier recommendations from CHMP for sarcoidosis; however the frequency category is rare instead of unknown as one case has been reported from a clinical study. Since a case of T-cell type acute leukemia has been reported from a clinical study, the SmPC has been updated to change the frequency of leukemia from “not known” to “rare”, and remove the asterisk noting that leukemia has not been observed in clinical studies with golimumab.

Safety update related to neurological event
Scope: A paragraph has been added to section 4.8, stating that a greater incidence of demyelination (Neurological events) was observed in the golimumab 100 mg group compared with the golimumab 50 mg group. A cross-reference to section 4.8 has been added in the Neurological events paragraph in section 4.4.
Background: This change was proposed further to an additional review of demyelination events conducted to evaluate the occurrence of demyelinating disorders in the 100 mg group relative to 50 mg group.

Updated on 16 June 2011 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to side-effects
  • Change to date of revision

Updated on 12 May 2011 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The Simponi SmPC has been updated to add information relating to transplacental transfer of golimumab to section 4.6. 

Section 4.6: Pregnancy now reads:

There are no adequate data on the use of golimumab in pregnant women. Due to its inhibition of TNF, golimumab administered during pregnancy could affect normal immune responses in the newborn. Studies in animals do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). The use of golimumab in pregnant women is not recommended; golimumab should be given to a pregnant woman only if clearly needed.

Golimumab crosses the placenta. Following treatment with a TNF-blocking monoclonal antibody during pregnancy, the antibody has been detected for up to 6 months in the serum of the infant born by the treated woman. Consequently, these infants may be at increased risk of infection. Administration of live vaccines to infants exposed to golimumab in utero is not recommended for 6 months following the mother’s last golimumab injection during pregnancy (see sections 4.4 and 4.5).

Section 4.4 and 4.6 of the SmPC have minor edits as a result of this change.

Updated on 10 May 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to information about pregnancy or lactation
  • Change to date of revision

Updated on 15 March 2011 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text
  • Change to marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8 of the SmPC has been updated to include vasculitis (systemic) as a rare side effect to Immune system disorders and vasculitis (cutaneous) as an uncommon side effect to Skin and subcutaneous tissue disorders.

These adverse drug reactions (ADR) were added to the SmPC following a request from the US Food and Drug Administration (FDA) to all manufacturers of TNFα blockers that vasculitis may be a potential safety issue associated with this class of drugs. The Marketing Authorisation Holder (MAH) reviewed the data on vasculitis to determine whether it should be added as an ADR for golimumab in the core reference labeling.

Also included in this revision is the change in the name of the MAH from Centocor B.V. to Janssen Biologics B.V.

 

Updated on 11 March 2011 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 23 February 2011 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update of section 4.1 of the SmPC (and related sections of the PL) to extend the indication in rheumatoid arthritis (RA) to include adult patients not previously treated with MTX; and addition of an indication for reduction in the rate of progression of joint damage in all RA populations. Related changes are made in section 5.1. In addition, changes have been introduced related to the SmPC guideline and implementation of the current QRD template.
Update of section 4.4 and 4.8 of the SmPC to add safety information regarding demyelinating disorders and update of section 4.4 regarding congestive heart failure.
Update of section 4.4 and 4.8 of the SmPC with additional safety information regarding serious hypersensitivity reactions.
Update of section 4.4. of the SmPC to add a recommendation for routine hepatitis B virus (HBV) testing as well as a recommendation to consult with a hepatitis B expert for patient tested positive for HBV infection.

Updated on 18 February 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
  • Change to dosage and administration

Updated on 1 December 2010 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Text has been added on the maintenance of treatment effect in patients with rheumatoid arthritis (RA), the revisions are based on data from the on going study in patients with inadequate response to DMARDS, data was provided up to week 104. For the 50 mg + MTX group it was determined that 54% (48/89) of subjects remained on the approved dose throughout the 2 years period. The ACR20/50/70 responses for these patients at week 104 have been added to section 5.1 of the SmPC, as well as information on maintenance of improvement in HAQ and SF-36 physical compontent.

The update of the information on immunogenicity data in section 5.1 was also supported appropriately by summarised data from all Phase 3 studies with golimumab in rheumatologic indications.

Updated on 16 September 2010 SmPC

Reasons for updating

  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 5.2 of the pre-filled Pen (PFP) and pre-filled syringe (PFS) SmPC has been revised to include updated PK information. To support these changes PK data from for the recently completed Phase 1 study C0524T14 were provided. The primary objective of C0524T14 was to investigate the PK of sc and iv golimumab after repeated administrations to subjects with RA

Updated on 9 September 2010 PIL

Reasons for updating

  • Change to date of revision
  • Change to improve clarity and readability

Updated on 4 June 2010 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 27 May 2010 PIL

Reasons for updating

  • New PIL for new product